{"id":75584,"date":"2026-08-20T12:28:40","date_gmt":"2026-08-20T04:28:40","guid":{"rendered":"https:\/\/flcube.com\/?p=75584"},"modified":"2026-08-20T12:28:40","modified_gmt":"2026-08-20T04:28:40","slug":"chinas-cde-opens-public-comment-on-pioneer-program-for-cell-and-gene-therapy-products-capping-intake-at-15-drugs-per-year","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75584","title":{"rendered":"China&#8217;s CDE Opens Public Comment on &#8220;Pioneer Program&#8221; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> released work documents for the <strong>&#8220;Pioneer Program&#8221; for cell and gene therapy (CGT) products<\/strong>, which will be open for <strong>public comment for one month<\/strong> from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a <strong>maximum of 15 drugs per year<\/strong> with access to expedited regulatory services.<\/p>\n\n\n\n<h2 id=\"h-program-overview\" class=\"wp-block-heading\">Program Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Authority<\/strong><\/td><td>CDE of the NMPA (China)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>&#8220;Pioneer Program&#8221; for cell and gene therapy (CGT) products<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Work documents released; open for public comment<\/td><\/tr><tr><td><strong>Comment Period<\/strong><\/td><td>One month from date of issuance (19 Aug 2026)<\/td><\/tr><tr><td><strong>Annual Capacity<\/strong><\/td><td>Maximum 15 drugs per year<\/td><\/tr><tr><td><strong>Key Benefit<\/strong><\/td><td>Expedited pre\u2011submission consultation services for included products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-eligibility-criteria\" class=\"wp-block-heading\">Eligibility Criteria<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Category 1 \u2013 Innovative Drugs (New Targets or New Mechanisms)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Applicable to drugs for the prevention and treatment of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Serious life\u2011threatening diseases<\/strong><\/li>\n\n\n\n<li><strong>Major chronic diseases:<\/strong> cardiovascular and cerebrovascular diseases, respiratory diseases, neurodegenerative diseases, metabolic diseases, and immune system diseases<\/li>\n\n\n\n<li><strong>Genetic diseases<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Requirements:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Address conditions with <strong>no currently effective prevention or treatment options<\/strong>, or demonstrate <strong>clinical value compared to existing therapies<\/strong><\/li>\n\n\n\n<li><strong>New target drugs:<\/strong> exert therapeutic effects through targets different from those of already marketed drugs<\/li>\n\n\n\n<li><strong>New mechanism drugs:<\/strong> exert therapeutic effects through mechanisms of action different from those of already marketed drugs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Category 2 \u2013 Manufacturing Process Optimization<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Major changes in manufacturing process optimization<\/strong> for already marketed drugs<\/li>\n\n\n\n<li>Drugs applying to the program multiple times under this category will be <strong>counted as a single drug<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-program-benefits\" class=\"wp-block-heading\">Program Benefits<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Products included in the Pioneer Program may apply for <strong>expedited pre\u2011submission consultation services<\/strong> \u2014 providing earlier, faster regulatory engagement with the CDE during development.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective Fast\u2011Track Design:<\/strong> Capping the program at 15 drugs per year signals a highly curated pathway, concentrating CDE resources on the most differentiated CGT candidates and raising the bar for inclusion.<\/li>\n\n\n\n<li><strong>Manufacturing Recognized as Critical:<\/strong> By extending eligibility to major manufacturing process optimization for marketed drugs, the CDE acknowledges that process innovation \u2014 often the key cost and scalability bottleneck for CGT \u2014 merits regulatory priority.<\/li>\n\n\n\n<li><strong>Strategic Signal for CGT Developers:<\/strong> The program reinforces China&#8217;s push to lead in cell and gene therapy, offering developers of new\u2011target and new\u2011mechanism assets a clearer route to accelerated regulatory interaction.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief describes a proposed regulatory framework currently open for public comment. Final requirements, eligibility determinations, and implementation timelines may differ from the draft work documents issued by the CDE.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ec6\u80de\u4e0e\u57fa\u56e0\u6cbb\u7597\u836f\u54c1\u5148\u9510\u8ba1\u5212\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u7ec6\u80de\u4e0e\u57fa\u56e0\u6cbb\u7597\u836f\u54c1\u201c\u5148\u9510\u8ba1\u5212\u201d\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.\"><\/object><a id=\"wp-block-file--media-bf5ac604-a643-4163-b196-cd9ea4821baf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ec6\u80de\u4e0e\u57fa\u56e0\u6cbb\u7597\u836f\u54c1\u5148\u9510\u8ba1\u5212\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\">\u7ec6\u80de\u4e0e\u57fa\u56e0\u6cbb\u7597\u836f\u54c1\u201c\u5148\u9510\u8ba1\u5212\u201d\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ec6\u80de\u4e0e\u57fa\u56e0\u6cbb\u7597\u836f\u54c1\u5148\u9510\u8ba1\u5212\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bf5ac604-a643-4163-b196-cd9ea4821baf\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u5148\u9510\u8ba1\u5212\u7533\u8bf7\u8868\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u201c\u5148\u9510\u8ba1\u5212\u201d\u7533\u8bf7\u8868\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.\"><\/object><a id=\"wp-block-file--media-d0804f73-4196-47c1-9d96-4f207673d922\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u5148\u9510\u8ba1\u5212\u7533\u8bf7\u8868\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\">\u201c\u5148\u9510\u8ba1\u5212\u201d\u7533\u8bf7\u8868\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u5148\u9510\u8ba1\u5212\u7533\u8bf7\u8868\uff08\u5f81\u6c42\u610f\u89c1\u7a3f\uff09.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d0804f73-4196-47c1-9d96-4f207673d922\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) released work&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,4],"tags":[102,77,66,14],"class_list":["post-75584","post","type-post","status-publish","format-standard","hentry","category-company","category-policy-regulatory","tag-cde","tag-cell-therapy","tag-gene-therapy","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s CDE Opens Public Comment on &quot;Pioneer Program&quot; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released work documents for the &quot;Pioneer Program&quot; for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75584\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s CDE Opens Public Comment on &quot;Pioneer Program&quot; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released work documents for the &quot;Pioneer Program&quot; for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75584\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T04:28:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s CDE Opens Public Comment on &#8220;Pioneer Program&#8221; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year\",\"datePublished\":\"2026-08-20T04:28:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\",\"Cell-therapy\",\"Gene therapy\",\"NMPA\"],\"articleSection\":[\"Company\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75584#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75584\",\"name\":\"China's CDE Opens Public Comment on \\\"Pioneer Program\\\" for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-20T04:28:40+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released work documents for the \\\"Pioneer Program\\\" for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75584\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75584#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s CDE Opens Public Comment on &#8220;Pioneer Program&#8221; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's CDE Opens Public Comment on \"Pioneer Program\" for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released work documents for the \"Pioneer Program\" for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75584","og_locale":"en_US","og_type":"article","og_title":"China's CDE Opens Public Comment on \"Pioneer Program\" for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released work documents for the \"Pioneer Program\" for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.","og_url":"https:\/\/flcube.com\/?p=75584","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-20T04:28:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75584#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75584"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s CDE Opens Public Comment on &#8220;Pioneer Program&#8221; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year","datePublished":"2026-08-20T04:28:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75584"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE","Cell-therapy","Gene therapy","NMPA"],"articleSection":["Company","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75584#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75584","url":"https:\/\/flcube.com\/?p=75584","name":"China's CDE Opens Public Comment on \"Pioneer Program\" for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-20T04:28:40+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released work documents for the \"Pioneer Program\" for cell and gene therapy (CGT) products, which will be open for public comment for one month from the date of issuance. The proposed program creates a selective, high\u2011priority pathway for breakthrough CGT products, accepting a maximum of 15 drugs per year with access to expedited regulatory services.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75584#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75584"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75584#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s CDE Opens Public Comment on &#8220;Pioneer Program&#8221; for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75584"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75584\/revisions"}],"predecessor-version":[{"id":75587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75584\/revisions\/75587"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}